Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:

– What are the differences between Clinical Development and Medical Affairs?

– When should a company start telling their medical story about a new product?

– What are the differences between drugs and vaccinations from a medical affairs’ perspective?

– And how should market access and medical affairs ideally work together?

Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 

Don’t miss this amazing conversation. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations

#pricing #medtech #pharmaceuticals #usa #innovation #vaccination 

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.                                                           

Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points: 

Will patients need and want the new product?

Will physicians prescribe it?

Will payers pay for it?

And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany

In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs – are there any relationships?

The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #fda

Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant – with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication.

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on “How to Embed AI into the Market Access Process“:  https://eularis.com/resources 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence